Date of event
Add to Calendar 2019-10-04 08:00:00 2019-10-05 14:00:00 AASLD / EASL ALD Conference This meeting will bridge critical gaps in ALD diagnosis, management and clinical trial design. 1 W. Wacker Drive Chicago, IL 60601 United States AASLD America/New_York public

Course Description / Needs Statement

Leading experts in the field of alcoholic liver disease (ALD) research and therapy will explore multiple aspects of managing patients. The Improving Outcomes in Alcohol-associated Liver Disease Through Robust Basic and Translational Research meeting will bridge critical gaps in ALD diagnosis, management and clinical trial design. Speakers will present evidence-based knowledge on ALD’s potential triggers, the role of alcohol dependence in management, various stages of disease, gender differences, and potential biomarkers for diagnosis, disease severity and prognosis. The program will include practical guidance on ways to create effective multidisciplinary teams to manage ALD patients, where hepatologists, addiction specialists, social workers, nurses and a patient’s family members work together as a team.

Program Chairs

  • Michael Lucey, MD, FAASLD
  • Philippe Mathurin, MD, PhD
  • Gyongyi Szabo, MD, PhD, FAASLD
  • Mark Thursz, MD

Scientific Program Advisor

  • Vijay Shah, MD, FAASLD


Download the AASLD / EASL ALD syllabus.


  • Renaissance Chicago Downtown Hotel
    1 W. Wacker Drive
    Chicago, IL 60601
    Phone: 312-372-7200

Learning Objectives

At the conclusion of this activity, participants will be able to:

  • Define the various stages and presentations of alcoholic liver disease and alcoholic hepatitis.
  • Present improved management and treatment options to patients with ALD based on expert recommendations.
  • Review challenges in clinical trial design, patient enrollment and outcomes in ALD.

Continuing Education

Continuing education will not be provided for this conference.

Travel Note

US residents: Please review the Real ID Act regarding boarding federally regulated commercial aircrafts. Depending on your state of residence, you may need to provide a second form of identification at the airport.

Schedule Note

Breakfast is served at 7 am ET both days.

Moderators: Gyongyi Szabo, MD, PhD, FAASLD and Giovanni Addolorato, MD

  • 8:00 am – 8:20 am ET
    Epidemiology of AALD
    Suthat Lianpunsakul, MD, MPH, FAASLD
  • 8:20 am – 8:40 am ET
    Moderate Alcoholic Hepatitis: What is it, and How Should it Be Studied?
    Ramon Bataller, MD, PhD
  • 8:40 am – 9:00 am ET
    Alcohol-associated Fibrosis and Cirrhosis: Clinical Research Opportunities and Needs in this Patient Population
    Mack C. Mitchell, MD, FAASLD
  • 9:00 am – 9:20 am ET
    NASH-AALD Overlap Syndromes
    Quentin M. Anstee, MBBS, PhD, FRCP
  • 9:20 am – 9:40 am ET
  • 9:40 am – 10:10 am ET

Moderators: Vijay Shah, MD, FAASLD and Alexandre Louvet, MD

  • 10:10 am – 10:30 am ET
    Key Features of the Patho-mechanisms of AALD and Alcoholic Hepatitis Including Gut-liver Axis and the Microbiome
    Gyongyi Szabo, MD, PhD, FAASLD
  • 10:30 am – 10:50 am ET
    Bile Acids - FGF19 and Cholestasis, Liver Regeneration, and Biologic Targets
    Bernd Schnabl, MD
  • 10:50 am – 11:10 am ET
    Impact of Infection on Progression of AALD: Mechanisms of Susceptibility and Management, Immunosuppression, and Biomarkers of Infection
    Nikhil Vergis, MRCP
  • 11:10 am – 11:30 am ET
    ACLF Specificity in ALD
    Christophe Moreno, MD, PhD
  • 11:30 am – 12:00 pm ET
  • 12:00 pm – 1:00 pm ET

Moderators: Mark Thursz, MD and Jessica L. Mellinger, MD

  • 1:00 pm – 1:20 pm ET
    Natural History of Alcohol Use Disorder and Psychological Health of Patients AUD: How Psychological Co-morbidities Interact with AUD
    Thomas P. Beresford, MD
  • 1:20 pm – 1:40 pm ET
    Treating Patients with Alcohol Use Disorder: Lessons for the Hepatology Community from the Addiction Medicine and Integrating AUD Treatment into the Care of Liver Disease Patients
    Giovanni Addolorato, MD
  • 1:40 pm – 2:00 pm ET
    Use of Validated Questionnaires and Biomarkers to Monitor Alcohol Use in Clinical Trials
    Lorenzo Leggio, MD, PhD, MSc
  • 2:00 pm – 2:20 pm ET
    Clinical Trial Design: Endpoints for AUD in Liver Patients
    Jessica L. Mellinger, MD
  • 2:20 pm – 2:40 pm ET
  • 2:40 pm – 3:00 pm ET

Moderators: Michael Lucey, MD, FAASLD and Christophe Moreno, MD, PhD

  • 3:00 pm – 3:20 pm ET
    Current Landscape in Liver Transplantation in the US and Europe: Selection Criteria and Social Factors
    Michael R. Lucey, MD, FAASLD
  • 3:20 pm – 3:40 pm ET 
    Relapse of Alcohol After Liver Transplantation
    Georges-Philippe Pageaux, MD, PhD
  • 3:40 pm – 4:00 pm ET
    Debate on Selection Criteria for Liver Transplantation for AALD: Liberalize Criteria
    Gene Y. Im, MD
  • 4:00 pm – 4:20 pm ET
    Debate on Selection Criteria for Liver Transplantation For AALD: Restrict Criteria
    James Neuberger, MD, FAASLD
  • 4:20 pm – 4:40 pm ET
    Liver Transplantation for AALD: How Can We Construct Robust Clinical Studies
    Norah Terrault, MD, MPH, FAASLD
  • 4:40 pm – 5:00 pm ET
    Current Landscape in Clinical Trials and Evolving Targets
    Vijay Shah, MD, FAASLD
  • 5:00 pm – 5:15 pm ET
  • 5:15 pm – 6:30 pm ET
    Group Discussions
    1. Which biologic targets offer the best hope for clinical study?
    2. Use of biomarkers in clinical studies?
    3. Monitoring for, and analyzing for the impact of return to alcohol use in the longer-term studies.
    4. Optimizing end-points for phase I, II and III studies, and how should surrogate alternatives to mortality be adopted in the short-term.
    5. Creating a consensus around criteria for selection for liver transplantation of AALD patients with short duration of abstinence.
  • 6:30 pm – 7:30 pm ET
    Poster Reception

Moderators: Philippe Mathurin, MD, PhD and Veronica Pei, MD, MEd, MPH

  • 8:00 am – 8:20 am ET
    Severe AH: Future Studies in Phase I & II Clinical Trials: Endpoints, Duration, Monitoring Alcohol Relapse, Use of Surrogate Endpoints, Including Biomarkers
    Philippe Mathurin, MD, PhD
  • 8:20 am – 8:40 am ET
    Severe AH: Future Phase III Studies: End-points, Duration, Monitoring Alcohol Relapse, Use of Surrogate Endpoints, Including Biomarkers
    Mark Thursz, MD
  • 8:40 am – 9:00 am ET
    Moderate AH: Challenges to Clinical Trials in AALD: Recruiting Subjects to Meet Power Assessments, End-points, Duration, Monitoring Alcohol Relapse, Endpoints, Use of Surrogate Endpoints, Including Biomarkers
    Alexandre Louvet, MD
  • 9:00 am – 9:20 am ET
    Alcoholic Cirrhosis: Challenges to Clinical Trials in AALD: Recruiting Subjects to Meet Power Assessments, End-points, Duration, Monitoring Alcohol Relapse, Endpoints, Use of Surrogate Endpoints, Including Biomarkers
    Timothy R. Morgan, MD, FAASLD
  • 9:20 am – 9:40 am ET
    Studies of Natural History to Develop Virtual Placebo Controls
    Veronica Pei, MD, MEd, MPH
  • 9:40 am – 9:55 am ET
  • 9:55 am – 10:05 am ET

Moderators: Gyongyi Szabo, MD, PhD, FAASLD and Shiv K. Sarin, MD, FAASLD

  • 10:05 am – 10:25 am ET
    AALD in Women
    Marsha Morgan, MD
  • 10:25 am – 10:45 am ET
    Nutrition in AALD
    Craig J. McClain, MD, FAASLD
  • 10:45 am – 11:05 am ET
    Liver Regeneration in AALD
    Bin Gao, MD, PhD
  • 11:05 am – 11:25 am ET
    Special Considerations and Opportunities in AALD Clinical Trials in Countries of APASL
    Shiv K. Sarin, MD, FAASLD
  • 11:25 am – 11:45 pm ET
    Special Considerations and Opportunities in AALD Clinical Trials in Countries of ALEH
    Juan P. Arab, MD
  • 11:45 am – 12:05 pm ET
  • 12:05 pm – 12:15 pm ET
    Closing Remarks
    Gyongyi Szabo, MD, PhD, FAASLD

US Residents: Review the Real ID Act regarding boarding federally regulated commercial aircrafts. Depending on your state of residence, you may need to provide a second form of identification at the airport.


Renaissance Chicago Downtown Hotel
1 West Upper Wacker Drive
Chicago, IL 60601

Make your Online Reservations
Phone: 1-877-303-0104

If you are calling to make a reservation, let the hotel representative know you are attending the AASLD meeting.


Single/Double $245 per night plus tax

Cancellation Policy

All hotel room reservations must be cancelled within 48 hours of scheduled arrival date to receive a refund.


  • Chicago Midway International Airport (MDW) 12.1 miles
  • Chicago O'Hare International Airport (ORD) 18 miles

Ground Transportation

From Chicago Midway International Airport (MDW): $30
From Chicago O'Hare International Airport (ORD): $50

The nearest subway station to the Renaissance Chicago Downtown is 1 block away, at the intersection of N. State St. and E. Lake St. named Sate/Lake Station. Estimated subway fare is $2.50 from either airport.


Onsite parking at the hotel is $72 per day and off-site parking is $52 per day. Valet parking is $72 per day with in and out privileges. Large SUVs and oversized vehicles are prohibited.

Submission Deadlines

Abstract submission has closed.

  • Opened: Wednesday, June 19, 2019 - ET
  • Closed: Tuesday, September 3, 2019 - ET


Abstracts submitted will be reviewed by the Program Chairs for potential poster presentation. If selected, the presenting author will be required to accept the invitation to present, register for the conference, and provide current financial disclosure information.

Abstract notification will be sent to presenting authors by mid-August.


For questions about the abstract submission process, send an email to



The title should be brief, but long enough to identify the nature of the study. Omit author names and medical degrees and institutional appointments in the title. The maximum for the title character count is 300.

Abstract Body

The body of the abstract needs to include:

  • A background
  • Description of methods
  • Summary of results obtained
  • Statement of conclusion reached

There is a set 3,000 maximum character count for the abstract body.


You may include any supporting images/tables. Images and tables are not a part of the overall character count.
Accepted files: pdf, jpg, jpeg, png, csv, doc(x), and ppt under 5MB

Author Types

Only one presenting and corresponding author may be selected – see author definitions below

  • Co-Author – One of several authors who provided a significant contribution to the abstract.
  • Corresponding Author – This author will receive all notifications regarding the abstract, and will be expected to make any changes requested by the abstract reviewers.
  • Presenting Author – The author who will be presenting the poster at the meeting.

The maximum number of authors on an abstract is 30.


For questions about the abstract submission process, send an email to

Ethics Policy

The initial responsibility for adherence to ethical guidelines lies with the responsible investigators submitting their research findings to AASLD meetings or journals. First, for reports of research using human subjects, provide assurance that (a) informed consent in writing was obtained from each patient and (b) the study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a prior approval by the appropriate institutional review committee. Refer to individual patients by number, not by initials. HEPATOLOGY will only accept papers for review from liver transplant centers that explicitly state that no donor organs were obtained from executed prisoners or other institutionalized persons. Papers without such explicit statements will be returned without review.

Second, in studies involving animal experimentation, provide assurance that all animals received humane care according to the criteria outlined in the Guide for the Care and Use of Laboratory Animals [PDF] prepared by the National Academy of Sciences and published by the National Institutes of Health (NIH publication 86-23 revised 1985).

Disclosure Policy

It is the policy of the American Association for the Study of Liver Diseases (AASLD) to ensure balance, independence, objectivity, and scientific rigor in all its individually or jointly provided educational programs. All faculty/authors participating in any AASLD sponsored programs, as well as planners and committee members, are expected to disclose any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the continuing medical education program.

All abstract authors must complete their own financial disclosure statement either disclosing all financial relationships with commercial interests or indicating that none exist. Submitting authors will NOT be allowed to submit disclosures on a co-author's behalf.

A limited number of travel awards will be available for trainees in the field of hepatology with a special interest in the conference topic. In order to qualify for a travel award, an abstract on related research must be submitted and accepted.

Press Policies and Guidelines

The American Association for the Study of Liver Diseases provides credentialed media with complimentary press registration. Below is information on eligibility and the credentialing process.

Press Eligibility

Journalists, and contributing freelancers, employed by a recognized news organization are eligible to apply for press registration. To be eligible for press registration, media in all categories must be directly involved in the creation of news content for organizations that meet these criteria:

  • Publish original editorial news coverage in a regular news section
  • Have complete editorial freedom from advertisers, funders and/or sponsors
  • If sponsored, the outlet has multiple sponsors (no single-sponsored publications)
  • Advertisers, sponsors, paid editorial and other funding sources are clearly identified


Bloggers will receive press credentials on a case-by-case basis. Please include a link to recent liver disease, hepatology or health care science coverage with your registration for credentials. Finally, all blogs must demonstrate the dissemination of original, editorial news coverage and editorial freedom from advertisers and/or sponsors (single-sponsored blogs will not receive credentials; blogs with advertising must have multiple advertisers clearly identified).


Photographers, videographers, and/or other members of the multimedia team accompanying credentialed news outlets may register as media and provide a link to recent coverage from their team. Further credentialing may be required during the approval process.

NOTE: AASLD has the right to inspect the credentials of anyone registering as media and reserves the right to deny media registration to anyone who does not meet the above guidelines. AASLD also has the right to limit the number of media registrants from any one media outlet to ensure ample space for all media.

Ineligible Registrants

The following individuals are not eligible for press registration or access to the Newsroom:

  • Individuals who receive exhibitor passes
  • Publishers or a publications’ advertising, marketing, public relations, sales, circulation, or any other non-editorial function representatives
  • Industry/exhibitor press officers and their public relations consultants
  • Financial or business analysts
  • Educational program developers (including CME writers and editors)
  • Trade media management personnel
  • Editors, writers, and scientific advisory board members for journals that do not have editorial news sections
  • Companies or organizations producing publications, videos, and/or other electronic media intended for internal use, marketing, advertising, financial analysis, or public relations purposes
  • Media who produce a communications vehicle that is sponsored by a single organization or whose revenue for the publication or issue of a publication depends solely on coverage of 2019 AASLD/EASL ALD Endpoints Conference
  • Media who produce a communications vehicle that uses the AASLD’s name or logo, or the 2019 AASLD/EASL ALD Endpoints Conference name/logo to imply endorsement from AASLD

NOTE: AASLD prohibits the development of CME content based on information presented at its meetings. CME writers and editors, and those writers and editors working on behalf of organizations that have written CME based on AASLD meetings, are not eligible for press passes.

Prohibited Activities

  • Sales, marketing or representing a company for the purposes of obtaining advertising, subscriptions, selling photography/video production, or other products or services from any registrant or exhibitor
  • Misrepresentation of role or activities to obtain media registration
  • Developing or assisting in the development of continuing medical education programs
  • Soliciting presenters and/or attendees for inclusion in CME programs
  • Publishing or posting presentation slides, live streams of meeting presentations, or sharing copyrighted meeting materials without written permission.

Video/Audio Recording

Television and video crews are required to check in immediately with AASLD staff each day.

Television and video crews must be wearing press badges. Shooting schedules must be provided to AASLD staff in advance of the meeting.

Permission of the speaker and moderator must be obtained by the journalist before recording or photographing presentations. Artificial light and flash photography cannot be used during presentations. Handheld audio recorders and still cameras are acceptable, assuming that intellectual property copyrights are respected.

Under no circumstances may presentations be rebroadcasted.

Any images from the meeting should be credited to: 2019 AASLD/EASL ALD Endpoints Conference.

Use of Insignias and Logos

Insignias and logos of the AASLD, this meeting or AASLD Foundation are proprietary marks. Use of these in any fashion, by any entity, for any purpose, is prohibited without the written permission of AASLD. The use of insignias, logos and images that mislead the intended audience to believe that a piece or production is coming from the AASLD is strictly prohibited and will result in the denial of press credentials for future meetings.

Dedicated Websites and Newsletters

If you intend to present coverage of this meeting in a dedicated website or newsletter, please include the following disclaimer at the top of your piece: This information is brought to you by [insert organization name] and is not sponsored by, nor a part of, the Association for the Study of Liver Diseases or 2019 AASLD/EASL ALD Endpoints Conference. Additionally, you may not use the AASLD’s logo or name to imply affiliation.

AASLD reserves the right to request promotional activities violating this policy be edited or removed. Failure to comply with these guidelines may result in loss of press credentials for future meetings.

Applying for Press Credentials

Requests for press credentials should be sent to and must be sent by Friday, September 27, 2019 - ET. Onsite press registration cannot be accommodated. When sending your request for credentials, include two of the following:

  • Bylined news coverage
  • Copy of official press credentials
  • Assignment letter
  • Two recent posts about liver disease and/or health care (for bloggers)